Cerdulatinib - Portola Pharmaceuticals

Drug Profile

Cerdulatinib - Portola Pharmaceuticals

Alternative Names: PRT 2070; PRT-062070; RVT-502; RVT-502 - Dermavant Sciences

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Dermavant Sciences; NicOx; Portola Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Eye disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Skin disorders
  • No development reported Allergic rhinitis; Eye-Disorders

Most Recent Events

  • 09 Dec 2017 Additional pharmacodynamics data from a phase I/IIa trial in B-cell lymphomas presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 23 Jun 2017 Interim efficacy data from a phase II trial in Haematological malignancies released by Portola Pharmaceuticals
  • 22 Jun 2017 Updated efficacy and adverse events data from a phase II trial in Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top